A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
The purpose of this study is to compare the effects, good and/or bad, of cabozantinib (the study drug) with everolimus on participants and their metastatic renal cell carcinoma to find out which is better.
Locally advanced or metastatic renal cell carcinoma (mRCC).
Age ≥ 18, unresectable locally advanced or mRCC with one prior systemic treatment
18 - 100
Healthy Volunteers Needed
Duration of Participation
As long as participants are seeing clinical benefit